G9835 — Trastuzumab administered within 12 months of diagnosis
G9835 is a HCPCS Level II code for trastuzumab administered within 12 months of diagnosis. It belongs to the Procedures and Professional Services (Temporary) section. It was terminated on December 31, 2020 and is not valid on new claims.
This code has been terminated
CMS terminated G9835 on December 31, 2020. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for G9835
- Long descriptor
- Trastuzumab administered within 12 months of diagnosis
- Short descriptor
- Trastuz given w/in 12 mos dx
- Added
- January 1, 2017
- Terminated
- December 31, 2020
- BETOS
- Z2
- Pricing indicator
- 00 — Not priced by Part B
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Service not separately priced by Part B — not covered, bundled into another service, or used by Part A only.
Codes adjacent to G9835
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If G9835 is not quite right, the correct code is very often within a few positions of it.
- G9827Her2-targeted therapies not administered during the initial course of treatmentterminated
- G9828Her2-targeted therapies administered during the initial course of treatmentterminated
- G9829Breast adjuvant chemotherapy administeredterminated
- G9830Her-2/neu positive
- G9831Ajcc stage at breast cancer diagnosis = ii or iii
- G9832Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c
- G9833Patient transfer to practice after initiation of chemotherapyterminated
- G9834Patient has metastatic disease at diagnosisterminated
- G9836Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete)terminated
- G9837Trastuzumab not administered within 12 months of diagnosisterminated
- G9838Patient has metastatic disease at diagnosis
- G9839Anti-egfr monoclonal antibody therapy
- G9840Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab
- G9841Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab
- G9842Patient has metastatic disease at diagnosis
- G9843Ras (kras or nras) gene mutation
Questions about G9835
What is HCPCS code G9835?
G9835 is a HCPCS Level II code for trastuzumab administered within 12 months of diagnosis. It sits in the Procedures and Professional Services (Temporary) section.
Does Medicare cover G9835?
The CMS HCPCS file marks G9835 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is G9835 still valid?
No. G9835 was terminated on December 31, 2020 and should not be used on new claims.